May. 28, 2010
Pfizer Inc is said to have sold its swine vaccine unit in China to Harbin Pharmaceutical Group.
According the report, Pfizer will sell its RespiSure and RespiSure-One swine mycoplasma hyopneumoniae (MH) vaccines to Harbin Bio-Vaccine, an animal health unit of Harbin Pharmaceutical for US$ 50 million.
Pfizer is required to divest its swine flu business in China as a condition by the Chinese antitrust authorities for Pfizer’s last year $68 billion merger with Wyeth.
Harbin Pharmaceutical, which counts Warburg Pincus among its major shareholders, manufactures and distributes generic antibiotics in China.